Tbio LY75 Lymphocyte antigen 75

Protein Summary

Description

Acts as an endocytic receptor to direct captured antigens from the extracellular space to a specialized antigen-processing compartment (By similarity). Causes reduced proliferation of B-lymphocytes. This locus represents naturally occurring read-through transcription between the neighboring lymphocyte antigen 75 (LY75) and CD302 molecule (CD302) genes. Alternative splicing results in multiple transcript variants encoding fusion products that share sequence identity with each individual gene product. [provided by RefSeq, Nov 2010]

Uniprot Accession IDs

• O60449
• O75913
• Q53R46
• Q53TF5
• Q7Z575
• Q7Z577
• Ly-75

Gene Name

• LY75

Ensembl ID

• ENST00000263636
• ENSP00000263636
• ENSG00000054219

Symbol

• CD205
• CLEC13B
• LY75
• CD205
• Ly-75
• CLEC13B
• DEC-205
• gp200-MR6

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
kinase perturbation	0.81
microRNA	0.79
gene perturbation	0.78
PubMedID	0.75
virus perturbation	0.68

Protein Classes

No PANTHER Classes or DTO Classes found

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 267.22   (req: < 5)

Gene RIFs: 25   (req: <= 3)

Antibodies: 544   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 267.22   (req: >= 5)

Gene RIFs: 25   (req: > 3)

Antibodies: 544   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 6

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0